Small molecule · developed by Belite Bio
Tinlarebant (LBS-008, BPN-14967) is an orally administered tablet studied in healthy volunteers and in dry age-related macular degeneration, including geographic atrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05949593 | Phase 3 | Geographic Atrophy | Active not recruiting | BLTE |
| NCT05667688 | Phase 1 | Healthy Volunteer | Completed | BLTE |
| NCT04005807 | Phase 1 | Healthy Volunteers | Completed | BLTE |
| NCT03735810 | Phase 1 | Healthy Volunteer | Completed | BLTE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Geographic AtrophyDry Age-related Macular DegenerationHealthy Volunteer
Updated Nov 8, 2026. Something wrong or missing? Report it on the BLTE page.
See BLTE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BLTE catalysts and pipeline →